17 results about "CD70" patented technology

The disclosure provides anti-CD70 antibodies, antigen binding fragments thereof, chimeric antigen receptors (CARs) and engineered T cell receptors (TCRs) comprising an antigen binding molecule that specifically binds to CD70, polynucleotides encoding the same, and in vitro cells comprising the same. The polynucleotides, polypeptides, and in vitro cells described herein can be used in an engineered TCR and / or CAR T cell therapy for the treatment of a patient suffering from a cancer. In one embodiment, the polynucleotides, polypeptides, and in vitro cells described herein can be used for the treatment of multiple myeloma.

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.

Several embodiments of the methods and compositions disclosed herein relate to immune cells that are genetically edited, for example, using Crispr / Cas, to modulate, reduce or otherwise eliminate expression of one or more endogenous genes. In several embodiments, the edited cells are engineered to express a chimeric antigen receptor targeting a tumor antigen, for example CD19, ligands of the NKG2D receptor, CD70, and / or BCMA, among others. In several embodiments, the editing enhances one or more aspects of the efficacy of the immune cells in cellular immunotherapy including cytotoxicity (e.g., ADCC) and / or persistence.

The present application relates to the technical field of multi-gene detection, and in particular to a set of capture probes for follicular lymphoma multi-gene detection, a kit and a detection analysis method ARID1A, ARID1B, ATM, ATP6V1B2, B2M, BCL10, BCL2, BCL6, BCL7A, BTG1, BTG2, BTK, CARD11, CCND3, CD58, CD70, CD79A, CD79B, CDK4, CDKN2A The capture probe set comprises capture probes for specifically binding to 74 follicular lymphoma related genes, and the capture probe set preferably comprises nucleotides with sequences as shown in SEQ ID NO. 1-937. The probe set of the present application can realize one-time detection of variation in the full exon region of 74 follicular lymphoma related genes in the sample to be detected in the same system, has high specificity, high average sequencing depth and wide coverage area.

This application relates to methods for treating patients with reduced sensitivity to BCL-2 inhibitors. An antibody or antigen-binding fragment thereof that binds to CD70 is provided for treating myeloid malignancies in human subjects resistant to BCL-2 inhibitor treatment, and a method for treating myeloid malignancies in a subject, the method comprising (a) selecting a human subject with myeloid malignancies who has reduced sensitivity to or is refractory to BCL-2 inhibitors; and (b) administering the CD70-binding antibody or antigen-binding fragment thereof to the subject. In some embodiments, the myeloid malignancy is acute myeloid leukemia (AML). In some embodiments, the CD70-binding antibody is Cusatuzumab. In some embodiments, the BCL-2 inhibitor is co-administered with the CD70-binding antibody or antigen-binding fragment thereof. In some embodiments, the BCL-2 inhibitor is Venetoc.

The present disclosure relates to DNA constructs encoding CD19-specific chimeric antigen receptors (CARs) and other recombinant proteins, such as CD70-binding proteins or CD70-specific CARs, as well as engineered immune cells (e.g., CD19-specific CAR T cells or CD19 / CD70 dual CAR T cells) comprising the DNA constructs, methods of making the same, and uses thereof in therapeutic applications.

This disclosure relates to CRISPR-related systems and components for targeting, editing, and / or regulating CD70 (differentiation cluster 70) gene expression. This disclosure also relates to methods and applications relating to genetically modified cells, including T cells or T cell progenitor cells.

This invention belongs to the field of biomedical technology and discloses an anti-CD70 nanobody and its applications. Specifically, it discloses an anti-CD70 nanobody characterized by CD70 binding function and the ability to block the binding of the CD70-CD27 receptor ligand, and defines its specific amino acid sequence. This invention provides an anti-CD70 nanobody obtained by immunizing alpacas, exhibiting high affinity and specificity. It can be used for immunoblotting, enzyme-linked immunosorbent assay (ELISA) kits, flow cytometry detection and counting, and also for the treatment of diseases such as tumors and autoimmune diseases.

The present invention is directed to an engineered cell comprising a chimeric antigen receptor (CAR) on its surface specific for carbonic anhydrase XI (CAIX) and an antigen binding domain specific for cluster of differentiation 70 (CD70), and wherein the engineered cell is further engineered to express and secrete a bispecific antibody specific for PD-1 and an antigen binding domain specific for CTLA4.

Provided herein are polynucleotides, vectors, compositions and methods for preparing and using genetically modified immune cells that express a chimeric antigen receptor (CAR) and a CD70 short hairpin RNA (shRNA), as well as method of using such modified immune cells for treating diseases or disorders, such as cancer or autoimmune disorders.

This invention provides a probe library and kit for detecting genetic risk gene mutations in viral infections, belonging to the field of gene detection technology. The probe library and kit designed in this invention achieve, for the first time, the simultaneous detection of all mutations in the following 51 genetic risk genes for viral infections: CARMIL2, CCL2, CD27, CD70, CIB1, CTPS1, CXCR4, CYBC1(C17orf62), DBR1, FCGR3A, FCHO1, ICAM1, IFIH1, IFNAR1, IFNAR2, IFNGR1, IFNGR2, IL10, IL10RA, IL10RB, IL... The probe library and kit of this invention contain 18BP, IRF3, IRF7, IRF9, MAGT1, LIG1, MCM2, NOS2, OAS1, POLR3A, POLR3C, POLR3F, PRKCD, RASGRP1, SH2D1A, STAT1, STAT2, TBK1, TICAM1, TLR3, TLR7, TLR8, TMC6, TMC8, TNFRSF9, TRAF1, TRAF2, TRAF3, TYK2, UNC93B1, and XIAP. This invention's probe library and kit can be used for detecting genetic variations in the risk of viral infection in clinical settings, assessing an individual's genetic risk of viral infection, and has broad application prospects.

The present disclosure relates to a binding molecule for CD70 or an antigen-binding fragment thereof, a derivative comprising the binding molecule or the antigen-binding fragment thereof, and a pharmaceutical composition. In addition, the present disclosure further relates to a related use of the binding molecule or the antigen-binding fragment thereof in the treatment of cancer and detection and diagnosis.

The application provides a freeze-dried composition containing an anti-CD70-drug conjugate, which comprises ARX305 and pharmaceutically acceptable buffers, surfactants and freeze-drying protectants, wherein the pH value of the freeze-dried composition is 5.5-6.0. The application also provides a freeze-dried preparation containing an anti-CD70-drug conjugate and a preparation method thereof. The application also provides the use of the freeze-dried composition and the freeze-dried preparation. The freeze-dried composition and the freeze-dried preparation provided by the application have excellent product performance, can be used for treating various cancers, and the preparation method is simple, easy to operate, high in production efficiency, and has very important economic and social values.

Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.